Method to prepare a filler with hyaluronic acid base comprising a neutralization step

ABSTRACT

The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

FIELD OF THE INVENTION

Embodiments described here concern a method to prepare a filler with ahyaluronic acid base, which has better properties of chemical andphysical stability over time and optimal viscoelasticity to be injectedcutaneously.

In particular, the method according to the embodiments described hereconcerns a method to prepare a filler with a hyaluronic acid base (HA),which comprises a first step in which the hyaluronic acid is crosslinkedand a subsequent step to neutralize and hydrate the crosslinkedhyaluronic acid.

BACKGROUND OF THE INVENTION

It is known that hyaluronic acid is one of the fundamental components ofthe connective tissues of man and other mammals. It is a substancewidely present in the human body in the epidermal, epithelial and neuraltissues.

Hyaluronic acid gives the skin its peculiar properties of resistance andshape retention. A lack of hyaluronic acid causes a weakening of theskin, promoting the formation of wrinkles and imperfections.

The concentration of hyaluronic acid in the tissues of the human bodytends to decrease with advancing age, so that its function of tissuerepair is weakened. With progressive aging and after repeated exposureto ultra-violet sunrays, the epidermal cells decrease their productionof hyaluronic acid and their speed of degradation increases. At the sametime, the skin loses collagen, which is another natural substancenecessary for maintaining the skin in a young and resilient form. Withthe passage of time, the loss of hyaluronic acid and collagen in theepidermal tissues causes the formation of folds and wrinkles.

From the chemical point of view, hyaluronic acid (HA) is a polymercompound, definable as a glycosaminoglycan with an un-branchedpolysaccharide chain, produced by the condensation of thousands ofdisaccharide units, which are in turn formed by residues of glucuronicacid and M-acetylglucosamine.

Thanks to its high solubility in water, the molecule of the saltcorresponding to hyaluronic acid, that is, hyaluronate, is able tocomplex with many molecules of water reaching a high degree ofhydration.

Moreover, by using specific crosslinking agents and suitable operatingprocess conditions (temperature, pH, etc.), the extreme length of thehyaluronic acid molecule and its high degree of hydration allow themolecules to organize themselves to form a structure of the lattice type(crosslinked hyaluronic acid), so as to create a molecular scaffold tomaintain the shape and tone of the epidermal tissue.

In recent years, various formulations based on hyaluronic acid have beendeveloped for use in esthetic applications in order to fill wrinkles,folds and scars and, in general, to improve the appearance of the face,or to fill the lips.

These formulations are therefore in continuous development from thepoint of view of industrial research, and are very attractive from thecommercial point of view. Hyaluronic acid, being naturally contained inthe human body, is a filler that is well tolerated by the epidermaltissue. For this reason, the formulations based on HA are still todayconsidered the best epidermal fillers on the market, because they do notcarry the risk of allergic reactions by the skin.

Originally, the first formulations based on hyaluronic acid wereprepared in the form of particles or microspheres suspended in a gel.However, these fillers based on gelled microspheres had the disadvantageof poor stability over time, with a tendency to chemical degradation afew months after being injected into the skin. Therefore, frequentre-injections of the filler were required over time, in order tomaintain the repair and epidermal growth constant.

In more recent times the advantage has been discovered of subjecting thehyaluronic acid to a suitable crosslinking step by using specificcrosslinking agents, and thus fillers based on crosslinked hyaluronicacid are used in esthetic treatments of the face. In this case, thepolymer chains of hyaluronic acid are connected to each other toconstitute a lattice.

As examples of the most commonly used crosslinking agents, we can cite1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether(EDDE), diepoxyoctane and divinyl sulfone. The crosslinking step allowsto obtain a hydrogel polymer lattice, which is less soluble in water andmore resistant to degradation, so as to require less frequent cutaneousinjections than in the case of formulations based on non-crosslinkedhyaluronic acid.

However, the use of said crosslinking agents leads to the formation ofhydrogels of crosslinked HA which have an excessive level of swelling ofthe lattice, in the step where the hyaluronic acid is contacted with achemical neutralizing solution.

Furthermore, an important disadvantage deriving from the crosslinkingoperating conditions adopted in the state of the art is the formation offillers based on crosslinked HA with a poor homogeneity of distributionof the chemical-physical parameters (temperature, viscosity, density,etc.) inside the polymer lattice, in the sense that the homogeneity ofthe structure is interrupted by the unwanted presence of both airmicrobubbles and lumps of material, that is, narrow zones of thickenedmaterial.

This lack of homogeneity of the chemical-physical parameters inside theHA lattice has a negative effect on the chemical-physical stability ofthe filler prepared, so that its effectiveness over time isunsatisfactory and it is necessary to perform cutaneous re-injections offillers fairly frequently.

As a consequence of these disadvantages, there is a need to makeavailable in the field of esthetic medicine an innovative method toprepare a filler with a hyaluronic acid base, a method able to increaseits chemical-physical stability and duration over time of its repairingaction.

There is therefore a need to perfect a method to prepare a filler with ahyaluronic acid base which can overcome the disadvantages of the priorart.

In particular, it is a primary purpose of the present invention toprovide a formulation based on hyaluronic acid having better propertiesof homogeneity/uniformity of the different chemical-physical parameters,so as to increase its stability over time, after it has been used as anesthetic filler.

A second purpose of the method according to the invention is to obtain afiller with a crosslinked HA base having adjustable viscoelasticity in adesired range, by controlling the parameters that define thecrosslinking of hyaluronic acid and the subsequent hydration step.

Another purpose of the invention is to improve the efficiency ofpenetration of a neutralizing solution in the chemical neutralizationstep that follows the crosslinking of the hyaluronic acid, by means of aselection of innovative operating conditions during the neutralizationstep.

The Applicant has devised, tested and embodied the present invention toovercome the shortcomings of the state of the art and to obtain theseand other purposes and advantages.

SUMMARY OF THE INVENTION

The present invention is set forth and characterized in the independentclaims, while the dependent claims describe other characteristics of thepresent invention or variants to the main inventive idea.

Embodiments described here concern a method to prepare a filler with ahyaluronic acid (HA) base, which comprises a step in which thehyaluronic acid is crosslinked, and a subsequent step for theneutralization and hydration of the crosslinked hyaluronic acid.

The main advantage of the method claimed, which will be described indetail hereafter, is that the operating conditions used allow to obtainformulations with a hyaluronic acid base with innovative and improvingcharacteristics with regard to the homogeneity and uniformity of thedifferent chemical-physical parameters inside it (composition,temperature, viscosity, etc.). Consequently, its chemical-physicalstability over time, after cutaneous injection, is considerablyincreased.

A first aspect of the invention concerns a method to prepare a fillerwith a hyaluronic acid base comprising the crosslinking of thehyaluronic acid by means of the following steps:

A₁) mixing the following components in a reaction chamber equipped witha mixer: water, hyaluronic acid (HA), a crosslinking agent selected fromthe class of polyethylene glycols (PEG), a solution of alkali metalhydroxide;

A₂) dividing the mixture thus obtained into a number n of partialportions and transferring said partial portions to a sequence of ncontainers to subject them to an ultrasound treatment, the number n ofpartial portions and containers being comprised between 4 and 32,preferably between 8 and 20;

A₃) disposing the n containers comprising these partial portions ofmixture in an incubator for a period of time comprised between 4 and 8hours in order to terminate the crosslinking of hyaluronic acid andpromote the formation of a gel of crosslinked hyaluronic acid.

The particular operating conditions adopted during the steps A₁), A₂),A₃) described above, in particular the use of a crosslinking agentselected from the polyethylene glycols and the division of the reactionmixture into n partial portions (step A₂), lead to the formation of alattice of hyaluronic acid in a gel form with innovative characteristicswith respect to the state of the art techniques. Indeed, this lattice ofhyaluronic acid will have a much lower level of swelling during thesubsequent neutralization and hydration step.

Embodiments of the present invention also concern defining optimaloperating conditions during the chemical neutralization of thehyaluronic acid gel deriving from the crosslinking step described above.

A method to prepare a filler with a hyaluronic acid base is therefore asecond aspect of the present invention, and comprises the followingsteps:

-   -   A) crosslinking the hyaluronic acid by mixing the following        components in a reaction chamber: water, hyaluronic acid (HA), a        crosslinking agent selected from the class of polyethylene        glycols (PEG), a solution of alkali metal hydroxide, the mixing        time being comprised between 10 and 40 minutes    -   B) a chemical neutralization step of the crosslinked HA gel        obtained in step A) comprising:    -   B₁) preparing a neutralizing solution by mixing the following        components: water, hydrochloric acid HCl, a buffer agent,        optionally lidocaine derivatives thereof;    -   B₂) dividing the neutralizing solution thus obtained into a        number n of partial portions and transferring these partial        portions inside the n containers comprising the crosslinked HA        gel obtained from step A), where n is a whole number comprised        between 4 and 32, preferably between 8 and 20;    -   B₃) subjecting the n containers to mixing by means of a rotating        device, making them rotate around the axis of the rotating        device, so as to promote a penetration of the neutralizing        solution inside the hyaluronic acid gel, and obtain a filler of        crosslinked hyaluronic acid in the form of a hydrogel.

The particular operating conditions adopted during the neutralizing stepB), in particular the division (step B₂) of the neutralizing solutioninto a number n of partial portions, and the subsequent gentle rotationto which the n containers are subjected during step B₃), allow toimprove the penetration efficiency of the neutralizing solution insidethe crosslinked HA gel. Consequently, an improved homogeneity anduniformity of chemical-physical parameters inside the filler obtained isobtained.

A third aspect of the present invention also concerns a specificembodiment of the method to prepare a filler with a hyaluronic acidbase, which method comprises:

-   -   A) a crosslinking step of the hyaluronic acid comprising the        following steps:    -   A₁) mixing the following components (w/w) in a reaction chamber        for a time comprised between 10 and 40 minutes:        -   from 25 to 60% in weight of water;        -   from 6 to 18% in weight of hyaluronic acid;        -   from 25 to 60% in weight of a solution of alkali metal            hydroxide;        -   from 0.5 to 4% in weight of a crosslinking agent selected            from the class of polyethylene glycols;    -   A₂) dividing the mixture thus obtained into a number n of        partial portions and transferring these partial portions to a        sequence of n containers to subject them to an ultrasound        treatment, the number n of partial portions and containers being        comprised between 4 and 32;    -   A₃) disposing the n containers comprising these partial portions        of mixture into an incubator for a time comprised between 4 and        8 hours;    -   B) a chemical neutralization step of the crosslinked HA gel        obtained in step A) that comprises the following steps:    -   B₁) preparing a neutralizing solution by mixing the following        components (w/w):        -   from 78 to 98% in weight of water;        -   from 4 to 25% in weight of hydrochloric acid;        -   from 0.1 to 1.5% in weight of a buffer agent;        -   up to 1.5% in weight of lidocaine or its derivatives;    -   B₂) dividing the mixture thus obtained into a number n of        partial portions and transferring these partial portions inside        the n containers comprising the crosslinked HA gel obtained from        step A), where n is a whole number comprised between 4 and 32;    -   B₃) subjecting the n containers to mixing by means of a rotating        device, making them rotate around the axis of the rotating        device, so as to promote a penetration of the neutralizing        solution inside the hyaluronic acid gel, and obtain a filler of        crosslinked hyaluronic acid in the form of a hydrogel.

As well as the advantages correlated to the degree ofhomogeneity/uniformity of the different chemical-physical parameters(composition, viscosity, etc.) inside it and the consequent temporalincrease of its chemical-physical stability, the method according to theembodiments described here allows to suitably adjust the finalviscoelasticity of the filler prepared.

Indeed, the control of the crosslinking parameters and the subsequenthydration step of the gel, makes the product stable from thethermodynamic point of view, so that the rheology of the product is alsoadjusted and maintained under control. The adjustment of the finalviscoelasticity of the hyaluronic acid filler allows, in the case ofvery viscous fillers, to be able to select the type of syringe mostsuitable for viscous fluids, so that the cutaneous injection can beperformed without particular disadvantages linked to high viscosity.

Embodiments of the present invention also concern the use of lidocaineor its derivatives as an anesthetic agent during the chemicalneutralization step of the hyaluronic acid gel.

A method to prepare a filler with a hyaluronic acid base is thus anotheraspect of the invention, which comprises the following steps:

-   -   A) crosslinking the hyaluronic acid by mixing the following        components in a reaction chamber: water, hyaluronic acid (HA), a        solution of alkali metal hydroxide, a crosslinking agent        selected from polyethylene glycol diglycidyl ether (PEG DE),        polypropylene glycol diglycidyl ether (PPG DE) and        polytetramethylene glycol diglycidyl ether, the mixing time        being comprised between 10 and 40 minutes; B) a neutralization        step in which the crosslinked HA gel obtained from the        crosslinked step A) is contacted with a neutralizing solution        comprising the flowing components: water, hydrochloric acid HCl,        a buffer agent, lidocaine or its derivatives functioning as an        anesthetic agent.

These and other aspects, characteristics and advantages of the presentdisclosure will be better understood with reference to the followingdescription, drawings and attached claims. The drawings, which areintegrated and form part of the present description, show some forms ofembodiment of the present invention, and together with the description,are intended to describe the principles of the disclosure.

The various aspects and characteristics described in the presentdescription can be applied individually where possible. These individualaspects, for example aspects and characteristics described in theattached dependent claims, can be the object of divisional applications.

It is understood that any aspect or characteristic that is discovered,during the patenting process, to be already known, shall not be claimedand shall be the object of a disclaimer.

DETAILED DESCRIPTION OF SOME EMBODIMENTS

We will now refer in detail to specific embodiments of a method for thepreparation of a filler with a hyaluronic acid base (HA), which providesfor the steps of crosslinking A) and neutralization B).

Each embodiment is supplied by way of illustration of the invention andshall not be understood as a limitation thereof.

Before describing these embodiments, we must clarify that thephraseology and terminology used here is for the purposes of descriptiononly, and cannot be considered as limitative.

All percentages and ratios indicated concern the weight of the totalcomposition (w/w), unless otherwise indicated. All percentage intervalsreported here are provided with the provision that the sum with respectto the total composition is 100%, unless otherwise indicated.

All the intervals reported shall be are understood to include theextremes, including those that show an interval “between” two values,unless otherwise indicated.

The present description also includes the intervals that derive fromuniting or overlapping two or more intervals described, unless otherwiseindicated.

The present description also includes the intervals that can derive fromthe combination of two or more values taken at different points, unlessotherwise indicated.

Embodiments described here concern the preparation of a filler with ahyaluronic acid base which can be used in the cosmetic treatment of theface, in particular to fill wrinkles, folds and scars and, in general,to improve the appearance of the face.

As we said, the crosslinking step A) is carried out by crosslinkingagents selected from polyethylene glycols (PEG). In particular, thecrosslinking step A) comprises a sequence of at least three steps A₁),A₂) and A₃).

Sub-step A₁) involves mixing the following components in a reactionchamber: water, hyaluronic acid (HA), a crosslinking agent selected fromthe polyethylene glycol class (PEG), a solution of alkali metalhydroxide.

The mixing step A₁) of the above components is carried out at atemperature between 10° C. and 30° C., preferably between 15° C. and 25°C., with a mixing time conveniently comprised between 10 and 40 minutes,preferably between 15 and 25 minutes.

With regard to the specific composition of the mixture, the percentageby weight (w/w) of the individual components with respect to the totalweight of the mixture can be as follows:

-   -   from 25 to 60% water;    -   from 6 to 18% hyaluronic acid (HA),    -   from 25 to 60% solution of alkali metal hydroxide,    -   from 0.5 to 4% of a crosslinking agent selected in the class of        polyethylene glycols (PEG).

Preferably but not necessarily, the mixing step A₁) of the componentsindicated can be carried out in two successive steps. In a first step wehave the preliminary mixing of water, hyaluronic acid (HA) fed in excessof the water, and a polyethylene glycol with a mixing time maintainedbetween 2 and 6 minutes.

After this period of time, the solution of alkali metal hydroxide,preferably sodium hydroxide NaOH, is added to the mixture obtained, andthe mixing of the components is continued for a time comprised between 8and 25 minutes, preferably between 10 and 20 minutes.

Among the various compounds of the PEG class, it has been noted that, interms of viscoelastic properties of the HA filler prepared, the bestresults are obtained by using as crosslinking agents bifunctional PEGshaving two epoxy groups at the end of the polymer chain. Among them wecan cite, for example, polyethylene glycol diglycidyl ether (PEG DE),polypropylene glycol diglycidyl ether (PPG DE) and polytetramethyleneglycol diglycidyl ether.

In the subsequent step A₂) the mixture obtained is divided into a numbern of partial portions, where n is a whole number comprised between 4 and32, preferably between 8 and 20. These partial portions of mixture aretransferred and fed to a sequence of corresponding n containers tosubject them to an ultrasound treatment.

The ultrasound treatment of the n containers is carried out by means ofsound waves with a frequency comprised between 40 and 60 kHz.

Moreover, the step A₂) of ultrasound treatment is generally carried outat a temperature comprised between 20 and 30° C., for a durationcomprised between 5 and 15 minutes.

The ultrasound treatment with the above operating conditions proved tobe particularly effective for separating and removing the airmicrobubbles, which can form during the mixing steps, from the mixture.The air microbubbles represent zones of discontinuity of material insidethe formulation obtained, and therefore their presence could compromisethe final viscoelastic properties of the filler prepared.

After the ultrasound treatment, the n containers comprising the npartial portions of mixture are disposed inside an incubator to completethe crosslinking reaction between the hyaluronic acid and thepolyethylene glycol, that is, performing step A₃) of the method inaccordance with the present description. Setting the temperature to aconstant value comprised between 25° C. and 35° C., the n containers areleft inside the incubator for a period of time comprised between 4 and 8hours, preferably between 5 and 7 hours. After this period of time, thecrosslinking of the hyaluronic acid can be defined as terminated, sothat a crosslinked hyaluronic acid gel is obtained inside eachcontainer.

The crosslinking step A) is carried out in a basic environment due tothe presence of a strong base such as sodium hydroxide: therefore, atthe end of the crosslinking, hyaluronic acid is obtained in gel formhaving a pH comprised between 10 and 14.

With these basic characteristics, the gelled formulation obtainedabsolutely cannot be used for esthetic treatments, as it would causeswelling and burning to the skin, besides being thermodynamicallyunstable. In fact, at pH values higher than 8, hydrolysis phenomenabecome likely, which are able to degrade the chemical structure of thehyaluronic acid hydrogel.

The subsequent step B) of neutralizing the HA gel therefore becomesnecessary, using a strong acid such as hydrochloric acid.

As explained previously, the neutralization step B) also comprises asequence of sub-steps B₁), B₂) and B₃).

In step B₁) a neutralizing solution is prepared by mixing the followingcomponents: water, hydrochloric acid HCl and a buffer agent. Thepercentage by weight (w/w) of the individual components with respect tothe total weight of the neutralizing solution is as follows:

-   -   from 78 to 98% water;    -   from 4 to 25% hydrochloric acid;    -   from 0.1 to 1.5% buffer agent.

As a buffer agent in step B₁) phosphoric acid, potassium phosphate,sodium phosphate can be used. Preferably, phosphoric acid is used.

According to a preferred embodiment, the neutralizing solution canoptionally also comprise small quantities of lidocaine or itsderivatives, preferably lidocaine hydrochloride is used. This categoryof compounds are known for their local anesthetic effect, so they havethe advantage of reducing itching or burning of the skin during thesubcutaneous injection of HA filler. In this case, the percentage byweight (w/w) of lidocaine or its derivatives, with respect to the totalweight of the solution, is generally maintained below 1.5%.

According to another preferred embodiment, the neutralizing solution canoptionally also comprise small quantities of glycine and/or proline. Thepresence of these two amino acids has proved advantageous, since theyhave the dual function of acting as thermodynamic stabilizers of thesolution, and of being precursors of the formation of collagen, thusincreasing the efficiency of the filler prepared in repairing thetissues.

In this case too, the total percentage by weight (w/w) of proline and/orglycine with respect to the weight of the neutralizing solution isgenerally maintained below 1%.

In accordance with the present invention, it is convenient to divide(step B₂) the neutralizing solution into a number n of partial portions,in the same way as in step A₂), n being a whole number comprised between4 and 32, preferably between 8 and 20.

The partial portions n of neutralizing solution are then transferredinto the n containers comprising the crosslinked HA gel obtained fromstep A).

We then proceed to step B₃), which consists in mixing the contents ofthe n containers using a rotating device: the n containers are put in agentle rotation around the axis of the rotating device for a durationcomprised between 140 and 200 hours.

During the mixing step B₃) the temperature is maintained at a valuecomprised between 20° C. and 30° C., while the speed of rotation of then containers around the axis of the rotating device is maintained at arather low value, generally comprised between 40 and 60 rpm.

The particular mixing method described above, inside portions of limitedmass, promotes a homogeneous penetration of the neutralizing solutioninside the crosslinked hyaluronic acid gel contained in the ncontainers.

At the same time as the chemical neutralization performed by the actionof the hydrochloric acid, an effective penetration of the watermolecules inside the meshes of the lattice of gelled hyaluronic acidalso takes place: therefore, a considerable hydration of the crosslinkedHA gel occurs, with consequent formation of a hydrogel. In practice, themeshes of HA lattice swell due to the penetration of the watermolecules, and the degree of swelling of the lattice is indicated by theterm “swelling”.

It has been proven experimentally that the use of a crosslinking agentselected from polyethylene glycols, as in the method according to thepresent description, entails a lower degree of swelling of the gelled HAlattice during step B) of neutralization and hydration of the gel.

The hydrogel filler of crosslinked hyaluronic acid obtained from step B)has a complex viscosity that can be comprised between 15 and 45 Pa*s(measured by Kinexus rheometer at 25° C.).

The HA filler in the form of hydrogel obtained in step B) is thensubjected to a pH control to verify the effectiveness of the chemicalneutralization that has taken place. Consequently, the pH value insidethe n containers must be neutral, that is, comprised in a range between6.5 and 7.5.

Finally, after the pH control test, the hydrogel filler of crosslinkedHA prepared by the method described here is suitable to be insertedinside cartridges for syringes for cutaneous injection.

Before being used, the filler storage cartridges have to be subjected tosterilization in autoclave. Autoclave sterilization is performed for 16minutes at a temperature of 121° C.

To sum up, compared with conventional methods for preparing formulationsbased on crosslinked hyaluronic acid, the method according to theembodiments described here allows to prepare a crosslinked HA fillerwhich has the following advantages:

1) Innovative and improved characteristics with regard to thehomogeneity and uniformity of the different chemical-physical parameters(composition, temperature, viscosity, etc.) inside the filler prepared.It follows that its chemical-physical stability over time, aftercutaneous injection, is considerably increased.

2) Adjustment of the final viscoelasticity of the filler prepared by anappropriate selection of the operating conditions during step A) and B)of the method. In this way, the desired rheological properties of thefiller are obtained, so that it is possible to select the mostappropriate type of syringes for sub-cutaneous injection according tothe viscosity of the filler to be injected.

3) The use of a crosslinking agent selected from polyethylene glycolsaccording to the present description involves a lower degree of swellingof the gelled lattice of HA during step B) of neutralization andhydration of the gel. A lower degree of swelling of the lattice isdesirable, since it allows to control and limit excess swelling duringthe sub-cutaneous injection step.

4) The particular operating conditions adopted during the neutralizationstep B) improve the efficiency of penetration of the neutralizingsolution inside the crosslinked HA gel. This aspect also contributes toimproving the homogeneity and uniformity of the chemical-physicalparameters inside the filler obtained.

It is also obvious that, although method according to the presentinvention has been described with reference to the embodiments of thecrosslinking step A) and neutralization step B) as described above, aperson of skill in the art shall certainly be able to achieve many otherequivalent forms of a method having the characteristics as set forth inthe claims and hence all coming within the field of protection definedthereby.

1. Method to prepare a filler with a hyaluronic acid base comprising thefollowing steps: A) crosslinking the hyaluronic acid by mixing thefollowing components in a reaction chamber: water, hyaluronic acid (HA),a solution of alkali metal hydroxide, a crosslinking agent chosen frompolyethylene glycol diglycidyl ether (PEG DE), polypropylene glycoldiglycidyl ether (PPG DE) and polytetramethylene glycol diglycidylether, the mixing time being comprised between 10 and 40 minutes; B) aneutralization step in which the gel of crosslinked HA obtained from thecrosslinking step A) is put in contact with a neutralization solutioncomprising the following components: water, hydrochloric acid HCl, abuffer agent, lidocaine or derivatives thereof as an anesthetic agent.2. Method as in claim 1, characterized in that in said crosslinking stepA) the reaction mixture is subjected to an ultrasound treatment for atime comprised between 5 and 15 minutes.
 3. Method as in any claimhereinbefore, characterized in that said ultrasound treatment in step A)is performed by acoustic waves with a frequency comprised between 40 and60 kHz.
 4. Method as in any claim hereinbefore, characterized in that atthe end of said crosslinking step A) hyaluronic acid is obtained in theform of a gel with a pH comprised between 10 and
 14. 5. Method as in anyclaim hereinbefore, characterized in that in said step B) the percentagein weight (w/w) of the individual components with respect to the totalweight of the neutralization solution is as follows: from 78 to 98%water; from 4 to 25% hydrochloric acid; from 0.1 to 1.5% buffer agent;up to 1.5% in weight of lidocaine or derivatives thereof.
 6. Method asin any claim hereinbefore, characterized in that said anesthetic agentused in the neutralization step B) is lidocaine hydrochloride.
 7. Methodas in any claim hereinbefore, characterized in that said buffer agent instep B) is chosen from phosphoric acid, potassium phosphate, sodiumphosphate.
 8. Method as in any claim hereinbefore, characterized in thatsaid neutralization solution in step B) also comprises glycine and/orproline to a total percentage of weight (w/w) with respect to the weightof the solution of less than 1%.
 9. Method as in any claim hereinbefore,characterized in that the hydrogel filler of crosslinked HA obtained instep B) is subjected to a pH control, to check that its value iscomprised in the range between 6.5 and 7.5.
 10. Method as in any claimhereinbefore, characterized in that, after verification of the pH, saidhydrogel filler of hyaluronic acid is inserted inside cartridges forinjection syringes, which are subjected to sterilization in autoclavesat 121° C. for 16 minutes.